Abstract
The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostate adenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient in these studies received androgen deprivation therapy prior to RP. Eleven studies found no significant correlation between focal NED and outcomes of interest, while five studies reported a significant association of focal NED assessed by immunohistochemical chromogranin A or serotonin staining with BCR or survival. Focal NED was associated with higher BCR rates after RP with a pooled HR of 1.39 (95% CI 1.07-1.81) in five studies. No heterogeneity was reported in this analysis (I2 = 21.7%, p = 0.276). In conclusion, focal NED in conventional PC is associated with worse prognosis after RP. Its presence should be reported in pathologic reports and its true clinical impact should be assessed in well-designed prospective controlled studies.
| Original language | English |
|---|---|
| Article number | 1374 |
| Journal | International journal of molecular sciences |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Mar 2 2019 |
Fingerprint
Keywords
- Chromogranin A
- Neuroendocrine differentiation
- Oncological outcome
- Prostate cancer
- Radical prostatectomy
- Survival
ASJC Scopus subject areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry
Cite this
Focal neuroendocrine differentiation of conventional prostate adenocarcinoma as a prognostic factor after radical prostatectomy : A systematic review and meta-analysis. / Parizi, Mehdi Kardoust; Iwata, Takehiro; Kimura, Shoji; Janisch, Florian; Abufaraj, Mohammad; Karakiewicz, Pierre I.; Enikeev, Dmitry; Rapoport, Leonid M.; Hutterer, Georg; Shariat, Shahrokh F.
In: International journal of molecular sciences, Vol. 20, No. 6, 1374, 02.03.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Focal neuroendocrine differentiation of conventional prostate adenocarcinoma as a prognostic factor after radical prostatectomy
T2 - A systematic review and meta-analysis
AU - Parizi, Mehdi Kardoust
AU - Iwata, Takehiro
AU - Kimura, Shoji
AU - Janisch, Florian
AU - Abufaraj, Mohammad
AU - Karakiewicz, Pierre I.
AU - Enikeev, Dmitry
AU - Rapoport, Leonid M.
AU - Hutterer, Georg
AU - Shariat, Shahrokh F.
PY - 2019/3/2
Y1 - 2019/3/2
N2 - The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostate adenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient in these studies received androgen deprivation therapy prior to RP. Eleven studies found no significant correlation between focal NED and outcomes of interest, while five studies reported a significant association of focal NED assessed by immunohistochemical chromogranin A or serotonin staining with BCR or survival. Focal NED was associated with higher BCR rates after RP with a pooled HR of 1.39 (95% CI 1.07-1.81) in five studies. No heterogeneity was reported in this analysis (I2 = 21.7%, p = 0.276). In conclusion, focal NED in conventional PC is associated with worse prognosis after RP. Its presence should be reported in pathologic reports and its true clinical impact should be assessed in well-designed prospective controlled studies.
AB - The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostate adenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient in these studies received androgen deprivation therapy prior to RP. Eleven studies found no significant correlation between focal NED and outcomes of interest, while five studies reported a significant association of focal NED assessed by immunohistochemical chromogranin A or serotonin staining with BCR or survival. Focal NED was associated with higher BCR rates after RP with a pooled HR of 1.39 (95% CI 1.07-1.81) in five studies. No heterogeneity was reported in this analysis (I2 = 21.7%, p = 0.276). In conclusion, focal NED in conventional PC is associated with worse prognosis after RP. Its presence should be reported in pathologic reports and its true clinical impact should be assessed in well-designed prospective controlled studies.
KW - Chromogranin A
KW - Neuroendocrine differentiation
KW - Oncological outcome
KW - Prostate cancer
KW - Radical prostatectomy
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85063628702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063628702&partnerID=8YFLogxK
U2 - 10.3390/ijms20061374
DO - 10.3390/ijms20061374
M3 - Review article
C2 - 30893781
AN - SCOPUS:85063628702
VL - 20
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 6
M1 - 1374
ER -